Featured News

Want to get involved in celiac disease research? It’s time to take action. The TEV-CeD Study is a phase 1b clinical trial testing the investigational medication TEV-53408 for the treatment of celiac disease.  

New research indicates that a specific set of natural memory T cells, when triggered by gluten, rapidly become destructive and cause intestinal damage in celiac disease patients.

The ILLUMINATE Studies are phase 2 clinical research studies evaluating an investigational medication designed to reduce or eliminate the negative immune response to gluten in adults with celiac disease.

The Celiac Disease Foundation is proud to continue our partnership with the Celiac Disease Center at Columbia University in presenting an annual free livestream international symposium, this year titled "Celiac Disease: On the Horizon". Registration open now.

For the first time ever, access for funding for celiac disease research is being made available through the U.S. DOD Congressionally Directed Medical Research Programs (DOD-CDMRP) Peer Review Medical Research Program Listing.

Consider joining the CeDar Rose Study, a remote celiac disease study that will monitor individual gluten tolerance.

Consider joining the LILY Study, a phase 1 clinical trial for people with celiac disease investigating DONQ52, a new potential celiac disease treatment.

iCureCeliac® is the Foundation’s patient-powered tool that is the single best resource for celiac disease researchers around the world helping to accelerate the search for treatments and a cure.

The risk of developing CAD in celiac patients was found to be higher for white males, and patients with celiac disease and CAD are more likely to have disorders such as high cholesterol, type 2 diabetes, and iron-deficiency anemia.  

Last week in Washington, D.C., the Celiac Disease Foundation and our allies secured two critical wins in our mission to drive policy change to improve the health of those living with celiac disease.